 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
16 August 2005 | Volume 143 Issue 4 | Pages 251-264
Background: Lifestyle modification can forestall diabetes in high-risk people, but the long-term cost-effectiveness is uncertain.
Objective: To estimate the effects of the lifestyle modification program used in the Diabetes Prevention Program (DPP) on health and economic outcomes.
Design: Cost-effectiveness analysis using the Archimedes model.
Data Sources: Published basic and epidemiologic studies, clinical trials, and Kaiser Permanente administrative data.
Target Population: Adults at high risk for diabetes (body mass index >24 kg/m2, fasting plasma glucose level of 5.2725 to 6.9375 mmol/L [95 to 125 mg/dL], 2-hour glucose tolerance test result of 7.77 to 11.0445 mmol/L [140 to 199 mg/dL]).
Time Horizon: 5 to 30 years.
Perspective: Patient, health plan, and societal.
Interventions: No prevention, DPP's lifestyle modification program, lifestyle modification begun after a person develops diabetes, and metformin.
Measurements: Diagnosis and complications of diabetes.
Results of Base-Case Analysis: Compared with no prevention program, the DPP lifestyle program would reduce a high-risk person's 30-year chances of getting diabetes from about 72% to 61%, the chances of a serious complication from about 38% to 30%, and the chances of dying of a complication of diabetes from about 13.5% to 11.2%. Metformin would deliver about one third the long-term health benefits achievable by immediate lifestyle modification. Compared with not implementing any prevention program, the expected 30-year cost/quality-adjusted life-year (QALY) of the DPP lifestyle intervention from the health plan's perspective would be about $143 000. From a societal perspective, the cost/QALY of the lifestyle intervention compared with doing nothing would be about $62 600. Either using metformin or delaying the lifestyle intervention until after a person develops diabetes would be more cost-effective, costing about $35 400 or $24 500 per QALY gained, respectively, compared with no program. Compared with delaying the lifestyle program until after diabetes is diagnosed, the marginal cost-effectiveness of beginning the DPP lifestyle program immediately would be about $201 800.
Results of Sensitivity Analysis: Variability and uncertainty deriving from the structure of the model were tested by comparing the model's results with the results of real clinical trials of diabetes and its complications. The most critical element of uncertainty is the effectiveness of the lifestyle program, as expressed by the 95% CI of the DPP study. The most important potentially controllable factor is the cost of the lifestyle program. Compared with no program, lifestyle modification for high-risk people can be made cost-saving over 30 years if the annual cost of the intervention can be reduced to about $100.
Limitations: Results depend on the accuracy of the model.
Conclusions: Lifestyle modification is likely to have important effects on the morbidity and mortality of diabetes and should be recommended to all high-risk people. The program used in the DPP study may be too expensive for health plans or a national program to implement. Less expensive methods are needed to achieve the degree of weight loss seen in the DPP.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From the Archimedes Project, Kaiser Permanente, Oakland, California, and the American Diabetes Association, Alexandria, Virginia.
Note: The order of authorship for Drs. Eddy and Schlessinger is alphabetical.
Disclaimer: The views expressed herein are those of the authors and do not necessarily reflect those of Kaiser Permanente or the American Diabetes Association.
Grant Support: This analysis was funded by Kaiser Permanente. The validation of the Archimedes model was funded by a grant from the American Diabetes Association, supported in part by Bristol-Myers Squibb.
Potential Financial Conflicts of Interest: The American Diabetes Association, which provided funding for validation of the Archimedes model, has received grants from Bristol-Myers Squibb, the manufacturer of metformin.
Requests for Single Reprints: David M. Eddy, MD, PhD, 1426 Crystal Lake Road, Aspen, CO 81611; e-mail, eddyaspen{at}yahoo.com.
Current Author Addresses: Dr. Eddy: 1426 Crystal Lake Road, Aspen, CO 81611.
Dr. Schlessinger: 633 Swarthmore Avenue, Pacific Palisades, CA 90272.
Dr. Kahn: American Diabetes Association, 1701 North Beauregard Street, Alexandria, VA 22307.
Author Contributions: Conception and design: D.M. Eddy, L. Schlessinger, R. Kahn.
Analysis and interpretation of the data: D.M. Eddy, L. Schlessinger.
Drafting of the article: D.M. Eddy.
Critical revision of the article for important intellectual content: D.M. Eddy, L. Schlessinger, R. Kahn.
Final approval of the article: D.M. Eddy, L. Schlessinger, R. Kahn.
Provision of study materials or patients: D.M. Eddy, L. Schlessinger.
Statistical expertise: D.M. Eddy, L. Schlessinger.
Obtaining of funding: D.M. Eddy, R. Kahn.
Administrative, technical, or logistic support: D.M. Eddy, L. Schlessinger.
Collection and assembly of data: D.M. Eddy, L. Schlessinger. ARTICLE
Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  V. R. Aroda and R. Ratner Approach to the Patient with Prediabetes J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3259 - 3265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kahn, R. M. Robertson, R. Smith, and D. Eddy The Impact of Prevention on Reducing the Burden of Cardiovascular Disease Diabetes Care, August 1, 2008; 31(8): 1686 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kahn, R. M. Robertson, R. Smith, and D. Eddy The Impact of Prevention on Reducing the Burden of Cardiovascular Disease Circulation, July 29, 2008; 118(5): 576 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Approaches to Treatment of Pre-Diabetes and Obesity and Promising New Approaches to Type 2 Diabetes Diabetes Care, July 1, 2008; 31(7): 1461 - 1466. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Gillies, P. C Lambert, K. R Abrams, A. J Sutton, N. J Cooper, R. T Hsu, M. J Davies, and K. Khunti Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis BMJ, May 24, 2008; 336(7654): 1180 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C Goyder Screening for and prevention of type 2 diabetes BMJ, May 24, 2008; 336(7654): 1140 - 1141. [Full Text] [PDF]
|
|
|
|
|
|
R. Rizza, D. Eddy, and R. Kahn Cure, Care, and Commitment: What Can We Look Forward To? Diabetes Care, May 1, 2008; 31(5): 1051 - 1059. [Full Text] [PDF]
|
|
|
|
|
|
K. E. Heikes, D. M. Eddy, B. Arondekar, and L. Schlessinger Diabetes Risk Calculator: A simple tool for detecting undiagnosed diabetes and pre-diabetes Diabetes Care, May 1, 2008; 31(5): 1040 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Polak, Z Kovacova, C Holst, C Verdich, A Astrup, E Blaak, K Patel, J M Oppert, D Langin, J A Martinez, et al. Total adiponectin and adiponectin multimeric complexes in relation to weight loss-induced improvements in insulin sensitivity in obese women: the NUGENOB study. Eur. J. Endocrinol., April 1, 2008; 158(4): 533 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Svetkey, V. J. Stevens, P. J. Brantley, L. J. Appel, J. F. Hollis, C. M. Loria, W. M. Vollmer, C. M. Gullion, K. Funk, P. Smith, et al. Comparison of Strategies for Sustaining Weight Loss: The Weight Loss Maintenance Randomized Controlled Trial JAMA, March 12, 2008; 299(10): 1139 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association Diabetes Care, January 1, 2008; 31(Supplement_1): S61 - S78. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dalziel and L. Segal Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions Health Promot. Int., December 1, 2007; 22(4): 271 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Hoerger, K. A. Hicks, S. W. Sorensen, W. H. Herman, R. E. Ratner, R. T. Ackermann, P. Zhang, and M. M. Engelgau Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. Adults Diabetes Care, November 1, 2007; 30(11): 2874 - 2879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Bradley, C. W. Given, Z. Luo, C. Roberts, G. Copeland, and B. A. Virnig Medicaid, Medicare, and the Michigan Tumor Registry: A Linkage Strategy Med Decis Making, August 1, 2007; 27(4): 352 - 363. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C. Mason, R. L. Hanson, and W. C. Knowler Progression to Type 2 Diabetes Characterized by Moderate Then Rapid Glucose Increases Diabetes, August 1, 2007; 56(8): 2054 - 2061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Herman Diabetes Epidemiology: Guiding Clinical and Public Health Practice: The Kelly West Award Lecture, 2006 Diabetes Care, July 1, 2007; 30(7): 1912 - 1919. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gordon, N. Graves, A. Hawkes, and E. Eakin A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol Chronic Illness, June 1, 2007; 3(2): 101 - 129. [Abstract] [PDF]
|
|
|
|
 |
|
 J. P. Geyman Disease Management: Panacea, Another False Hope, or Something in Between? Ann. Fam. Med, May 1, 2007; 5(3): 257 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Franz The Evidence Is In: Lifestyle Interventions Can Prevent Diabetes American Journal of Lifestyle Medicine, March 1, 2007; 1(2): 113 - 121. [Abstract] [PDF]
|
|
|
|
|
|
American Diabetes Association Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association Diabetes Care, January 1, 2007; 30(suppl_1): S48 - S65. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kiberd The Chronic Kidney Disease Epidemic: Stepping Back and Looking Forward J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2967 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Nutrition Recommendations and Interventions for Diabetes-2006: A position statement of the American Diabetes Association. Diabetes Care, September 1, 2006; 29(9): 2140 - 2157. [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. O'Malley and P. Greenland The proof for prevention: beyond observations. Arch Intern Med, March 13, 2006; 166(5): 486 - 486. [Full Text] [PDF]
|
|
|
|
|
|
W. H. Herman, T. J. Hoerger, K. Hicks, M. Brandle, S. W. Sorensen, P. Zhang, M. M. Engelgau, R. F. Hamman, D. G. Marrero, R. T. Ackermann, et al. Managing People at High Risk for Diabetes Ann Intern Med, January 3, 2006; 144(1): 66 - 67. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Engelgau Trying To Predict the Future for People with Diabetes: A Tough but Important Task Ann Intern Med, August 16, 2005; 143(4): 301 - 302. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Brandeau Modeling Complex Medical Decision Problems with the Archimedes Model Ann Intern Med, August 16, 2005; 143(4): 303 - 304. [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
